Quantitative analysis for NRx Pharmaceuticals, Inc. (NRXP) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (28.0) (grade D). 27 signals analyzed (24 differentiated alt-data).
NRXP stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $3.10 | $2.88 | $2.95 |
| 2026-05-08 | $3.13 | $3.01 | $3.08 |
| 2026-05-20 | $3.02 | $2.86 | $2.97 |
| 2026-06-02 | $5.05 | $4.58 | $4.62 |
| 2026-06-12 | $3.99 | $3.80 | $3.84 |
| 2026-06-25 | $3.77 | $3.40 | $3.56 |
| 2026-07-08 | $4.25 | $3.88 | $3.92 |
| 2026-07-20 | $4.39 | $4.12 | $4.18 |
| 2026-07-30 | $3.15 | $2.82 | $3.12 |
| 2026-08-12 | $3.50 | $3.29 | $3.36 |
| 2026-08-24 | $3.61 | $3.44 | $3.45 |
| 2026-09-03 | $3.50 | $3.42 | $3.43 |
How NRx Pharmaceuticals, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ELUT | Elutia Inc. | $52M | — |
| COAG | Hemab Therapeutics Holdings, Inc. Common Stock | $53M | — |
| CUE | Cue Biopharma, Inc. | $54M | — |
| ACRV | Acrivon Therapeutics, Inc. Common Stock | $56M | — |
View all Health Care stocks by valuation and signals →
NRx Pharmaceuticals, Inc. (NRXP) scores Sell (28.0), and the composite conceals a 73-point disagreement between its dimensions. It is strongest on analyst consensus at 74, and weakest on technicals at 15 and competitive moat at 1. A stock can carry analyst consensus that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 74 |
| technicals | 15 |
| competitive moat | 1 |
StoQuant analyzes 27 signals (24 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on NRx Pharmaceuticals, Inc. (NRXP): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/NRXP"><img src="https://stoquant.com/badge/NRXP.svg" alt="NRx Pharmaceuticals, Inc. (NRXP) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.